Physician profile
Ann S Collins
NPI 1336120583
$6,593.07
in general payments reported to CMS, 2019-2025
51 companies · $704 in 2025
The $704 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $363 · 2021: $688 · 2022: $718 · 2023: $3,035 · 2024: $660 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723 · Travel and Lodging: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.89 |
| Travel and Lodging | $1,675.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $2,094.15 | 2023-2024 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $428.34 | 2019-2025 | |
| Abbvie INC. | $398.59 | 2019-2024 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Mayne Pharma Commercial LLC | $381.36 | 2022-2025 | |
| Pfizer INC. | $381.15 | 2019-2025 | |
| Exeltis, USA INC. | $302.61 | 2020-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $225.50 | 2019-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $166.06 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $147.77 | 2019-2021 | |
| Avion Pharmaceuticals | $142.04 | 2020-2022 | |
| Sage Therapeutics, LLC | $140.71 | 2021-2023 | |
| Astellas Pharma Global Development | $139.54 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $136.44 | 2021-2025 | Phexxi, Solosec, Phexx |
| Shield Therapeutics INC | $133.92 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $113.81 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $90.12 | 2023 | |
| Aspira Women'S Health INC | $89.36 | 2021-2024 | Ova1 |
| Coopersurgical, INC. | $89.16 | 2019-2025 | Summit Doppler, Endosee, Paragard T 380a |
| Gilead Sciences, INC. | $84.07 | 2020 | |
| Novo Nordisk INC | $78.66 | 2025 | Ozempic, Rybelsus, Wegovy |
| Myovant Sciences INC. | $76.18 | 2021-2022 | |
| Agile Therapeutics, INC. | $74.31 | 2021-2024 | Twirla |
| Organon LLC | $71.17 | 2022-2025 | Jada System, Nexplanon |
| Hologic Sales and Service, LLC | $54.30 | 2024-2025 | Acessa Provu System, Aptima, Novasure |
| Channel Medsystems, INC. | $54.07 | 2023-2024 | |
| Baxter Healthcare | $53.79 | 2021-2022 | |
| Duchesnay USA Incorporated | $43.90 | 2019 | |
| Amgen INC. | $39.90 | 2019-2021 | |
| Lupin INC. | $38.94 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.19 | 2022 | |
| Vertical Pharmaceuticals, LLC | $31.37 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.62 | 2019-2021 | |
| Allergan, INC. | $28.55 | 2020 | |
| Roche Diagnostics Corporation | $24.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.34 | 2020 | |
| Amag Pharmaceuticals, INC. | $24.23 | 2019 | |
| Ethicon US, LLC | $23.50 | 2019 | |
| Millicent US INC | $22.11 | 2021 | |
| Scynexis, INC. | $21.25 | 2022 | |
| Merck Sharp & Dohme LLC | $16.34 | 2019 | |
| Bausch Health US, LLC | $15.30 | 2020 | |
| Gynesonics, INC. | $12.77 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Meditrina | $12.61 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.